Novel Therapeutic Approach for Human T-cell Malignancies
Identification of Targetable Vulnerabilities in Redox Homeostasis Pathways as a Novel Therapeutic Approach for Human T-cell Malignancies
Istituto Oncologico Veneto IRCCS
120 participants
Jul 1, 2024
OBSERVATIONAL
Conditions
Summary
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
Eligibility
Inclusion Criteria4
- Patients with pre- and post-thymic T-cell leukemia/lymphoma
- Patients of both sexes
- Age of patients older than 18 years
- Patient is willing to provide written and signed informed consent for participation in the study
Exclusion Criteria1
- Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.
Interventions
Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06600568